Insights

Innovative HIV Therapy ImmunoScience's development of Contre Vir™ as a potential cure for HIV presents a groundbreaking treatment opportunity, especially appealing to healthcare providers and organizations involved in infectious disease management seeking advanced solutions.

Global Clinical Expansion With preliminary trials underway in the US, Europe, and Africa, the company's international trial plans indicate a readiness for collaboration and partnership with global healthcare institutions, biotech firms, and research organizations.

High Patent Portfolio The company's patents for Contre Vir™ underscore its proprietary technology, which can attract licensing, partnership, and investment opportunities, emphasizing its competitive edge in HIV therapeutic research.

Emerging Market Potential Given the high level of interest in several countries and the company's focus on final trial planning, there is a significant market opportunity for investors and partners looking to enter the HIV treatment space in emerging markets.

Technology and Innovation Utilizing standard web and biotech research tools, ImmunoScience’s emphasis on cutting-edge vaccine development highlights its potential to attract partnerships with larger biotech and pharmaceutical companies interested in innovative HIV therapies.

ImmunoScience, Inc. Email Formats	Example	Percentage
First.Last@immunoscience.com	John.Doe@immunoscience.com	100%

ImmunoScience, Inc. Email Formats

Example

Percentage

First.Last@immunoscience.com

John.Doe@immunoscience.com

100%

Frequently Asked Questions

Where is ImmunoScience, Inc.'s headquarters located?

ImmunoScience, Inc.'s main headquarters is located at United States. The company has employees across 2 continents, including North AmericaAsia.

What is ImmunoScience, Inc.'s phone number?

You can contact ImmunoScience, Inc.'s main corporate office by phone at

+1-925-460-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ImmunoScience, Inc.'s official website and social media links?

ImmunoScience, Inc.'s official website is immunoscience.com and has social profiles on LinkedIn.

What is ImmunoScience, Inc.'s SIC code NAICS code?

ImmunoScience, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ImmunoScience, Inc. have currently?

As of December 2025, ImmunoScience, Inc. has approximately 11 employees across 2 continents, including North AmericaAsia. Key team members include VP Marketing/Business Development: A. A.President: A. S.Vice President, Planning And Investor Communications: R. N.. Explore ImmunoScience, Inc.'s employee directory with LeadIQ.

What industry does ImmunoScience, Inc. belong to?

ImmunoScience, Inc. operates in the Biotechnology Research industry.

What technology does ImmunoScience, Inc. use?

ImmunoScience, Inc.'s tech stack includes DreamWeaverjQueryApache HTTP ServerNginxApache.

What is ImmunoScience, Inc.'s email format?

ImmunoScience, Inc.'s email format typically follows the pattern of First.Last@immunoscience.com. Find more ImmunoScience, Inc. email formats with LeadIQ.

ImmunoScience, Inc.

Q: What is ImmunoScience, Inc.'s official website and social media links?

ImmunoScience, Inc.'s official website is immunoscience.com. ImmunoScience, Inc. has social profiles on LinkedIn.

Q: How many employees does ImmunoScience, Inc. have currently?

ImmunoScience, Inc. has approximately 11 employees.

Q: What technology does ImmunoScience, Inc. use?

ImmunoScience, Inc.'s tech stack includes Apache HTTP Server, DreamWeaver, jQuery, Nginx, Apache.

Q: What is ImmunoScience, Inc.'s NAICS code?

ImmunoScience, Inc.'s NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchUnited States11-50 Employees

ImmunoScience, Inc. is a biotechnology research and development company specializing in the diagnosis and treatment of HIV. ImmunoScience's flagship product is Contre Vir™, a recombinant, live, attenuated therapeutic vaccine for the treatment and potential cure of AIDS and the HIV infection. Contre Vir™ has shown a very high level of success in pre-clinical studies and pilot clinical trials. Further studies are in final planning stages in several countries where interest is extremely high. ImmunoScience has several patents for Contre Vir™ across the globe and is expected to start Phase I clinical trials for Contre Vir™ in the very near future. The preliminary work for these trials is already underway in the United States, Belgium, Ghana and Uganda. ImmunoScience considers this invention to be a ground-breaking step forward in the fight against AIDS and HIV.

Insights

Similar companies to ImmunoScience, Inc.

Bio-Rad Laboratories

Roche

Danaher Corporation

Abcam

Thermo Fisher Scientific

Agilent Technologies

Siemens Healthineers